Price (delayed)
$1.24
Market cap
$67.02M
P/E Ratio
3.65
Dividend/share
N/A
EPS
$0.34
Enterprise value
$8.43M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
There are no recent dividends present for SPRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.